Spatial immune atlas of breast cancer brain metastasis reveals CD163+ macrophage reprogramming associated with immune escape

Product:
Mouse Panel 120
Topic:
Oncology
Disease Area:
Cancer
Sample Type:
Mouse CSF

Abstract

Background Brain metastases (BrM) remain a major cause of mortality in breast cancer (BC), yet the spatial organization and molecular circuitry of the metastatic immune microenvironment are poorly defined.

Methods To address this gap, we integrated high-plex imaging mass cytometry (IMC) performed on human primary breast tumors (n=20 regions of interests (ROIs)) and human brain-metastasis tissues (n=40 ROIs) with publicly available datasets, including single-cell RNA sequencing (scRNA-seq) from BC (n=10) and BrM (n=12) and spatial transcriptomic (ST) data from BC (n=7) and BrM (n=1), enabling single-cell resolution of tissue architecture, functional states, and intercellular signaling.

Results IMC resolved nine major cell classes and diverse epithelial, myeloid, and T-cell subtypes, and revealed a striking shift in macrophage polarization: CD163−CD11b− macrophages were markedly depleted in brain metastases, whereas CD163+ subsets persisted. Spatial analysis demonstrated the loss of the immune-permissive CN1 neighborhood in brain metastases, which is enriched in memory T cells, B cells, and dendritic cells, and the expansion of the immunosuppressive CN9 niche in brain metastases, containing CD163+ macrophages, invasion-like epithelial cells, and exhausted T cells. ScRNA-seq integration corroborated these findings by refining the annotation of major immune and stromal lineages and confirming CD163 expression patterns across macrophage subsets. ST deconvolution further reproduced these CN1-like and CN9-like domains in situ, validating their anatomical organization across BC and BrM. Ligand-receptor inference highlighted specific inhibitory pathways—including programmed cell death protein 1/programmed death-ligand 1, growth arrest-specific 6-Tyro3, Axl, and Mer receptor tyrosine kinase family, nectin cell adhesion molecule 2 (NECTIN2)-T-cell immunoreceptor with Ig and ITIM domains, and prostaglandin E2 (PGE2)-prostaglandin E2 receptor 4—that are associated with immune evasion and metastatic growth. Functional validation in an in vivo brain metastasis model further supported the therapeutic relevance of targeting these immunoregulatory pathways.

Conclusions Together, these findings show a shift from permissive to suppressive immune niches, accompanied by pronounced macrophage reprogramming, as central features of BC adaptation to the brain. This spatially resolved framework provides mechanistic insight into the poor responsiveness of brain metastases to current immunotherapies and identifies defined inhibitory ligand-receptor axes as actionable targets for combination immunotherapy.

Authors and Affiliations

Jiale Zhu¹˒², Junjie Ye¹, Yulin Ma¹, Zhirong Lin¹˒³, Yupeng Wen¹, Jianpeng Sheng⁴, and Mei Yang¹˒⁵

¹ Department of Breast Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
² Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
³ Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Zhujiang Hospital, Guangzhou, Guangdong, China
⁴ Chinese Institutes for Medical Research, Beijing, China
⁵ Department of Breast Cancer, Cancer Centre, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.